Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-11Estimated
Enrollment · participants1300Estimated
Source updated2026-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.